Company Overview
- Found by industry veterans, an unique sustainable platform developing novel small molecule medicines
- Using Structure-Based Drug Discovery approach and leverage cutting-edge synthetic methods to rationally design novel scaffolds with dual- or multi-kinase selectivity and excellent activity
- Comprehensive and proactive IP protection strategy including PCTs granted in China and Hong Kong, filed and under review in the U.S., Europe, Japan and South Korea
- Focused pipeline with a number of potential first-in-class and best-in-class assets in key therapeutic areas of oncology and cardiovascular diseases to address unmet needs globally
